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Background: Multipotent mesenchymal stem (stromal) cells (MSCs) have been credited with immunomodulative
properties, supporting beneficial outcomes when transplanted into a variety of disease models involving
inflammation. Potential mechanisms include the secretion of paracrine factors and the establishment of a
neurotrophic microenvironment. To test the hypothesis that MSCs release soluble mediators that can attenuate
local inflammation, we here analysed the influence of MSCs on the activation of microglia cells, as well as on
inflammatory parameters and pain behaviour in a surgical rat model of neuropathic pain.
Methods: We focussed on an experimental model of partial sciatic nerve ligation (PSNL), characterised by a
rapid and persistent inflammation in the dorsal lumbar spinal cord where sensory inputs from the sciatic
nerve are processed. Via indwelling intrathecal catheters, MSCs were repetitively grafted into the intrathecal
lumbar space. Animals were evaluated for mechanical and thermal hypersensitivity over a period of 21 days
after PSNL. Afterwards, spinal cords were processed for immunohistochemical analysis of the microglial marker ionized
calcium-binding adapter molecule 1 (Iba1) and quantification of inflammatory markers in ipsilateral dorsal horns. We
hypothesised that injections on postsurgical days 2 to 4 would interfere with microglial activation, leading to a reduced
production of pro-inflammatory cytokines and amelioration of pain behaviour.
Results: PSNL-induced mechanical allodynia or heat hyperalgesia were not influenced by MSC transplantation, and
spinal cord inflammatory processes remained largely unaffected. Indeed, the early microglial response to PSNL
characterised by increased Iba1 expression in the lumbar dorsal horn was not significantly altered and cytokine levels
in the spinal cord at 21 days after surgery were similar to those found in vehicle-injected animals. Grafted MSCs were
detected close to the pia mater, but were absent within the spinal cord parenchyma.
Conclusions: We conclude that intrathecal administration is not an appropriate route to deliver cells for treatment of
acute spinal cord inflammation as it leads to entrapment of grafted cells within the pia mater. We propose that the
early inflammatory response triggered by PSNL in the lumbar spinal cord failed to effectively recruit MSCs or was
insufficient to disturb the tissue integrity so as to allow MSCs to penetrate the spinal cord parenchyma.
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Partial sciatic nerve ligation (PSNL) is a commonly used
animal model for studying mechanisms underlying
neuropathic pain [1]. Hypersensitivity to mechanical and
thermal stimuli (mechanical allodynia and thermal
hyperalgesia) that develops rapidly after PSNL is at least
partly dependent on synaptic sensitisation processes
within the dorsal spinal cord to where sensory nerve
endings project [2]. Indeed, at the cellular level, nerve
injury leads to an activation of micro- and astroglial cells
within the ipsilateral dorsal horn of the spinal cord
concurrent with the release of a wide range of inflamma-
tory mediators, including pro-inflammatory cytokines
[3-5]. Glial cell activation has been implicated in the on-
set but also in the maintenance of pain hypersensitivity
[6,7]. Given the lack of effective treatments for neuro-
pathic pain [8], interventions targeting the neuroinflam-
matory activation cascades are considered as promising
therapeutic perspectives. Indeed, several studies with dif-
ferent anti-inflammatory and glia-modulating drugs
showed positive outcomes in a variety of experimental
paradigms, some of which are currently being tested in
clinical trials [3,9,10].
Convincing immunomodulatory features have been as-
cribed to mesenchymal stem (stromal) cells (MSCs) de-
rived from the bone marrow, an easily accessible and
highly proliferative stem cell source [11-14]. While the
prominent benefit provided by these multipotent adult
stem cells has been largely documented in several dis-
ease models, being characterised by inflammatory reac-
tions in the nervous system (such as amyotrophic lateral
sclerosis (ALS), Parkinson’s disease, Alzheimer’s disease
or traumatic injuries), it is noteworthy that the immuno-
modulatory capacity of grafted MSCs does not necessarily
depend on cell-specific differentiation or the integration
of the grafted cells into the host tissue. It rather seems
that MSCs possess the potential to establish a transient
neurotrophic microenvironment that is beneficial and
supports tissue healing, repair and regeneration. In fact,
grafted MSCs have been recently described as “in vivo
drugstores”, synthesising and secreting paracrine factors
which mediate therapeutic benefits [15-18]. Supporting
this concept, two in vitro studies have documented that
MSCs can release growth/neurotrophic factors as well
as anti-inflammatory proteins and modulate microglial
responses to pro-inflammatory stimuli [19,20]. More-
over, single intra-brain or intravenous injections were
shown to ameliorate neuroinflammation and associated
behaviour in animal models of neuropathic pain, such
as sciatic nerve constriction, contusion injury or spared
nerve injury [21-23].
In the present investigation, we validated the immuno-
modulatory effect of MSCs on primary microglial cul-
tures activated by bacterial lipopolysaccharide (LPS), aprototypical agonist of Toll-like receptor (TLR)4 serving
as a standard stimulus to trigger pro-inflammatory micro-
glial reactions. In vivo, MSCs were then repetitively
injected via the intrathecal route between 2 and 4 days
after PSNL or sham surgery. In this specific experimental
set up, behavioural assessments were performed to
explore whether the putative anti-inflammatory effect of
MSCs would influence PSNL-evoked mechanical allodynia
and thermal hyperalgesia.
Material and methods
Materials for cell culture
Culture media, foetal bovine serum (FBS), horse serum
(HS), penicillin-streptomycin, fungizone, proline, trypsin-
EDTA and PCR primers were purchased from Invitrogen
(Merelbeke, Belgium). Poly-L-lysine was obtained from
Sigma (Bornem, Belgium) and ultrapure Escherichia coli
LPS from InvivoGen (Toulouse, France). Percoll™/Redi-
Grad™ reagent was acquired from GE Healthcare
(Uppsala, Sweden). TriPure RNA Isolation Reagent was
bought from Roche Diagnostic (Vilvoorde, Belgium) and
iScript cDNA Synthesis Kit as well as IQ™ SYBR® Green
supermix from BioRad Laboratories (Nazareth, Belgium).
Culture plastic ware was purchased from Greiner Bio-one
(Wemmel, Belgium).
Generation of rat bone marrow-derived mesenchymal
stem cells and collection of conditioned medium
All experiments were performed in strict accordance
with the European Union directive of 22 September
2010 (2010/63/EU). For all in vivo experiments, female
Sprague Dawley rats were used and obtained from
Charles River (Brussels, Belgium). MSCs were isolated
from the bone marrow of tibias and femurs of 8-week-
old Sprague Dawley rats and cultured in uncoated tissue
culture flasks, as these cells readily adhere to the plastic.
Cells were propagated for 15 passages and then charac-
terised as previously described [24,25]. MSCs were har-
vested by trypsinisation and plated at a density of 1 × 105
cells per well in six-well plates in 2 ml DMEM with high
glucose, 10% FBS, 1% penicillin-streptomycin and 1%
fungizone. For in vitro experiments, the medium was
changed after 24 hours and cells were incubated for an-
other 48 hours. Supernatant (MSC-conditioned medium)
was then collected and centrifuged at 174 × g for 5 mi-
nutes to remove cell debris. Control medium was incu-
bated in culture flasks (containing no cells) for 48 hours
and also collected and centrifuged. MSC-conditioned
and control media were frozen and stored at -20°C until
further use. It is worth mentioning that the in vitro part
of this study only examined the influence of conditioned
medium from MSCs on cultured microglia and, there-
fore, the number of MSCs used to generate this condi-
tioned medium cannot be compared to the number of
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directly injected intrathecally.
Primary culture of microglial cells
Primary cultures were obtained from the cerebral cortices
of newborn wild-type Wistar rats as described before [26].
In brief, cells were obtained by a sedimentation protocol
and plated into 75 cm2 poly-L-lysine-coated flasks. The
culture medium was changed every 5 days. After 14 days
of culturing, cells were trypsinised and microglia were
separated from other cell types using a Percoll-density-
gradient centrifugation. The resulting cultures were highly
enriched in microglial cells and plated at a density of 3 ×
104 cells/cm2 in the same medium as used for MSC
cultures.
Activation of microglial cells
Twenty-four hours after plating, cell treatments were
initiated by either incubating cells for 24 hours in 2 ml
MSC-conditioned medium or in 2 ml control medium.
Then the media were removed and replaced by fresh
MSC-conditioned medium or control medium, this time
with or without LPS (100 ng/ml), leading to four differ-
ent culture conditions. After a 24-hour incubation
period, the cell plates were transferred onto ice, washed
with 1 × PBS, and TriPure Isolation Reagent was added
to each well. Until RNA extraction, samples were stored
at -20°C. This experiment was conducted in duplicates
and repeated six times.
RNA extraction, reverse transcription and real-time PCR
RNA was extracted according to the manufacturer’s
protocol and treated with DNAse at 37°C for 30 minutes.
Reverse transcription was carried out with the iScript
cDNA Synthesis Kit, using 1 μg RNA in a total reaction
volume of 20 μl. Real-time quantitative PCR was per-
formed for quantification of the genetic expression of
TNFα and IL-1β using the iCycler real-time PCR detec-
tion system (BioRad). Each reaction was carried out in a
total volume of 25 μl, containing 2 ng cDNA template,
350 nM of both specific forward and reverse primers
(TNFα forward: 5′-CCCCGACTATGTGCTCCTCAC-3′,
TNFα reverse: 5′-AGGGCTCTTGATGGCGGA-3′; IL-
1β forward: 5′-GGAAGGCAGTGTCACTCATTGTG-3′,
IL-1β reverse: 5′-GGTCCTCATCCT GGAAGCTCC-3′)
and the IQ SYBR Green super mix. The protocol con-
sisted of 50 amplification cycles, each conducted as fol-
lows: 15 seconds of denaturation at 95°C, 45 seconds
annealing at 60°C and 15 seconds of elongation at 79°C.
For quantitative analysis, a standard curve was generated
by amplification of serial dilutions of a cDNA template
mix, consisting of all analysed samples. Each sample was
normalised to the relative amplification of the house-
keeping gene glyceraldehyde 3-phosphate dehydrogenase(GAPDH). Raw data was analysed by the “post-run data
analysis” software provided by BioRad.
Behavioural testing
For behavioural analyses, animals were first habituated to
the testing procedures and surroundings. Procedures to
examine hyperalgesia and allodynia have been previously
described by our group in more detail [2]. To evaluate
thermal sensitivity, a Paw Thermal Stimulator (San Diego
University, CA, USA) was used, applying a beam of radi-
ant heat to the mid plantar surface of rat’s hind paws
(Hargreaves test). Paw withdrawal latencies (PWL) were
measured for both hind paws with a cut-off set at 20 sec-
onds to avoid tissue damage. For each time point, the
average PWL of at least four testing trials, each separated
by a 10-minute interval, was calculated per rat and nor-
malised to the baseline value (PWL before surgery).
Mechanical sensitivity was assessed with nine different
von Frey filaments (Stoelting Co., Wood Dale, IL, USA)
with a bending force from 0.4 g to 26 g, to determine the
50% paw withdrawal threshold (PWT), as previously de-
scribed [27]. Results are shown as a percentage of the
baseline value for each animal. The baseline values for the
rats were obtained by taking the average PWL and PWT
obtained in the 3 days preceding surgery. To rule out that
nociceptive thresholds were influenced by the catheter
implantation, PWL and PWT before and after catheter
implant were compared. Postoperative assessments of
pain behaviour were performed for 3 weeks after surgery,
more specifically on days 1, 2, 3, 4, 5, 6, 7, 10, 14, 17 and
20. With respect to the behavioural examinations, a total
of 9 to 11 animals were included in each group.
Intrathecal catheterisation
Previous studies proposed that the female system medi-
ating pathological pain has a substantially higher clinical
relevance than that of males, which essentially relies on
a TLR4-testosterone dependent pathway [28]. Also con-
sidering the higher incidence of chronic pain in women,
only female rats were used in the present study. Three-
month-old animals were anaesthetised by combined in-
traperitoneal injection of xylazine (10 mg/kg) and keta-
mine (80 mg/kg) and intrathecal polyethylene catheters
were implanted by first incising the atlanto-occipital
membrane and underlying dura mater and then carefully
advancing the tip of the catheter along the spinal cord
for a distance up to 8.5 cm, thereby reaching the lumbo-
sacral enlargement. Skin layers were closed with 2-0 su-
tures. After surgery, bladders were manually voided and
animals received 5 ml subcutaneous saline solution for
rehydration. As long as animals were anaesthetised, eyes
were regularly moistened with drops of isotonic NaCl
solution. Topical antibiotic treatment of the sutured
wound with Aureomycin® (Chlortetracyclin 1%, Erfa
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and once a day for the next 2 days. To keep catheters
free and unblocked by cell-clots, they were flushed daily
with 15 μl NaCl solution until cell treatment started.
Animals showing neurological deficits after surgery were
immediately euthanised. Several days after surgery, 15 μl
1% Xylocaine® (Lidocaine-hydrochloride 10 mg/ml,
AstraZeneca, Brussels, Belgium) was injected intra-
thecally to verify that the catheter was positioned cor-
rectly, causing temporary deficits in hind limb function.
Partial sciatic nerve ligation
Nine days after catheterisation, the animals were anaes-
thetised with sevoflurane (8% for induction; 4% for
maintenance; oxygen as carrier gas) and PSNL was per-
formed as previously described [2]. In brief, the right sci-
atic nerve was exposed at the mid-thigh level and
isolated from surrounding tissues. With a 6-0 suture,
one-third to one-half of the nerve trunk was tightly li-
gated above its bifurcation in peroneal and tibial
branches. Muscle and skin layers were finally closed with
a 2-0 suture. Sham surgeries involved identical proce-
dures, but without ligation of the sciatic nerve.
Stem cell injection
Considering our previous studies with MSCs maintained
in cultures for a prolonged time [24], we here exclusively
used cells grown in vitro for 15 passages, which corres-
pond to approximately 4 to 5 months. MSCs were first
labelled in vitro by adding bromodeoxyuridine (BrdU,
Sigma) (10 μM) to the culture medium 72 hours before
cell harvesting. Suspensions of MSCs were then obtained
by trypsinisation, two washes in PBS and resuspension
in OptiMEM (Invitrogen) at a density of 66,000 cells/μl
(1 million in 15 μl) for injection. This protocol was se-
lected as it permits the delivery of a large amount of
cells in a minimal volume, without clustering cells clot-
ting the catheters, which we observed during prelimin-
ary tests using 2 million cells in 15 μl. Fifteen μl of MSCFigure 1 Experimental design for in vivo experiments. ELISA, enzyme-lin
stem (stromal) cell; PSNL, partial sciatic nerve ligation.suspension or vehicle (OptiMEM) were then slowly
injected intrathecally followed by a 10 μl saline flush.
Avoiding any interference with the daily behavioural
measurements, cell injections took place in the evenings.
Cells were administered on days 2, 3 and 4 following
surgery, as summarised in Figure 1. Leftovers of cells
prepared for treatment were re-cultured to control via-
bility and BrdU-positivity after a few cell cycles.
Tissue collection
For immunohistochemistry, rats were killed by transcar-
diac perfusion with warm (37°C) saline solution (0.9%
NaCl) followed by cold 4% paraformaldehyde (dissolved
in PBS) under deep anaesthesia with xylazine (10 mg/kg)
and ketamine (80 mg/kg). Immediately after perfusion,
the spinal cord was isolated via hydro-extrusion and
post-fixed overnight in 4% paraformaldehyde at 4°C.
Tissues were cryo-protected by incubation in 15%
sucrose solution (in PBS) for 24 hours at 4°C, followed
by incubation in 30% sucrose solution for 2 days at 4°C.
The lumbar region of each spinal cord (L4-L6) was
quickly frozen (3 minutes in isopentane at -80°C) and
stored at -80°C until cryosectioning. In total, 3 to 4
spinal cord samples were collected per group on day 6
post-surgery and 5 to 7 samples per group on day 21
post-surgery. They were serially cut at -30°C to obtain
10 series of transverse 25 μm thick sections, which were
collected on ThermoScientific superfrost plus glass
slides (VWR International, Leuven, Belgium). Sections
were stored at -20°C until histological staining.
For ELISA, rats were euthanised with CO2 and de-
capitated. The spinal cord was rapidly isolated by
hydro-extrusion and transferred in cooled PBS solution
to carefully remove meninges. The lumbar enlargement
was isolated and ipsilateral and contralateral sides were
separated using the ventral fissure as a reference. Sub-
sequently, these halves were divided into dorsal and
ventral parts, using the central canal as a reference.
Tissues were stored in microtubes at -80°C until usedked immunosorbent assay; IHC, immunohistochemistry; MSC, mesenchymal
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used per group.
Immunohistochemistry and quantification
After thawing and drying overnight at 37°C, every tenth
section was stained for ionized calcium-binding adapter
molecule 1 (Iba1) and BrdU. For Iba1 staining, sections
were washed three times (3 × 10 minutes) in PBS before
incubation in a blocking solution (5% HS, 1% Triton in
PBS) for 90 minutes at room temperature (RT). The pri-
mary antibody against Iba1 (rabbit anti-rat Iba1, 1:1,000,
Wako Pure Chemical Ltd, Osaka, Japan) was diluted in a
PBS working solution containing 1% HS and 1% Triton
for an overnight incubation at 4°C. The next day, after
three washing steps (3 × 10 minutes) with PBS, sections
were incubated with the secondary antibody (donkey anti-
rabbit-Alexa488 antibody, 1:500, Invitrogen) diluted in the
same working solution for 1 hour at RT. After three washes
in PBS, nuclei were stained with DAPI (1:5,000) for 15 mi-
nutes at RT and, after washing sections three more times,
they were finally embedded in Fluoprep and cover-slipped.
For BrdU detection, DNA was denatured by boiling
the sections for 20 minutes in 10 mM citric acid at 96-
98°C. Afterwards, sections were allowed to cool down
(within the citric acid) for 30 minutes before being
washed three times (3 × 10 minutes) in PBS with 0.5%
Triton. After blocking for 90 minutes with 15% HS and
0.5% Triton in PBS at RT, sections were incubated with
the primary antibody diluted in blocking solution
(mouse anti-BrdU, 1:200, AbD Serotec, Düsseldorf,
Germany) for 2 nights at 4°C. After three washes in PBS
with 0.5% Triton, sections were incubated with the sec-
ondary antibody (goat anti-mouse-Alexa555 antibody,
1:500, Invitrogen) diluted in PBS with 0.5% Triton for
1 hour at RT. After three washes in PBS, nuclei were
stained with DAPI (1:5,000) for 15 minutes at RT; sec-
tions were washed three more times and finally embed-
ded in Fluoprep followed by cover-slipping.
Photo-micrographs of the ipsilateral dorsal horns were
taken using a fluorescent inverted microscope (EVOS fl,
AMG, Westburg, Leusden, The Netherlands) with a 4×
objective. An average of 7 sections (L4-L5) per animal
were analysed using ImageJ 1.44. The dorsal horn was
delineated and, after background subtraction, Iba1-
stained dorsal horns were analysed. The mean staining
intensity in the dorsal horn was calculated for each
photo-micrograph and data were plotted.
ELISA
Tissue samples were suspended in 200 μl lysis buffer
(Cell Signaling via New England Biolabs, Frankfurt,
Germany) and 2 μl PMSF (200 mM), then incubated on
ice for 5 minutes, sonicated and cleared by centrifuga-
tion (14,000 × g, 4°C, 10 minutes). Supernatants werecollected and their protein content was determined with a
MicroBCA assay (Pierce, Thermo Scientific, Bonn,
Germany). IL-1β, IL-6, IL-10 and TNFα were measured
using respective ELISA systems (R&D Systems, Wiesbaden,
Germany) according to the manufacturer’s instructions.
Absorbance was measured at 450 nm (with 540 nm
reference) using an iMark microplate reader (Bio-Rad,
Munich, Germany).
Statistical analyses
All data are presented as means ± SEM and statistical
analyses were performed with GraphPad Prism version
5.02 (GraphPad software, San Diego, CA, USA). Groups
were compared by a two-way analysis of variance,
followed by a Tukey post-hoc test correcting for multiple
comparisons. To determine differences between the
curves of behavioural data, the area under the curve was
calculated for each animal and averaged per treatment
group, so that treatment groups could be compared by a
two-tailed student’s t-test. Day-by-day group differences
between sham and PSNL or treated and untreated,
respectively, were calculated via whole sample t-tests.
Significant differences are indicated if P values were
below 0.05.
Results
Mesenchymal stem cell-conditioned medium reduces
microglial cytokine expression in response to
lipopolysaccharide
In vivo, neuroinflammation involves activation of micro-
glia, characterised by morphological changes, cell prolif-
eration and production of pro-inflammatory cytokines.
To test our hypothesis that MSCs release soluble media-
tors which can attenuate inflammation after peripheral
nerve injury (PNI), we first evaluated the influence of
MSC-conditioned medium on primary microglial cul-
tures exposed to an inflammatory stimulus (LPS). We
quantified the mRNA expression of the two key pro-
inflammatory cytokines TNFα and IL-1β (Figure 2). As
expected, exposure of microglial cells to LPS for 24 hours
increased the gene expression of both targets. This in-
creased expression induced by LPS could be significantly
attenuated in cells that had been exposed to MSC-
conditioned medium beforehand, demonstrating the im-
munomodulatory properties of soluble factors released
by MSCs.
Pain hypersensitivity is unaffected by mesenchymal stem
cell transplantation
Mechanical and thermal sensitivity were assessed during
20 days after sham or PSNL surgery. Figure 1 summarises
the different steps and time points of the experimental
design. When ipsilateral hind paws were stimulated with
von Frey filaments, a clear and significant decrease in the
AB
Figure 2 Modulation of lipopolysaccharide-induced expression
of inflammatory cytokines in primary microglial cultures. The
relative mRNA expression (normalised to glyceraldehyde 3-phosphate
dehydrogenase; GAPDH) of the pro-inflammatory cytokines TNFα
(A) and IL-1β (B) was examined in microglial cultures incubated for
48 hours in medium conditioned or not with MSCs and with or
without lipopolysaccharide (LPS; 100 ng/ml) during the last
24 hours. Data shown are mean values with SEM from six
independent experiments, analysed by two-way analysis of variance
followed by Tukey post-hoc test. ##P < 0.01 and ***/###P < 0.001.
Symbols denote significant differences between LPS-activated and
non-activated groups (*) and between control and conditioned
medium-treated groups (#).
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to their respective sham group. In contrast, no change in
PWT was observed upon stimulation of the contralateral
hind paws (Figure 3A-C). Heat stimulation of hind limbs
led to a very similar outcome, although the decrease in
the PWL was less prominent (Figure 3D-F). Altogether,
these results indicate that hypersensitivity after PSNL is
efficiently validated by the two behavioural tests.
Animals received vehicle or MSC injections in the eve-
nings of day 2, 3 and 4 after surgery, when peripheral
nerve injury-induced microglial activation was clearly
established [29]. Analysis of mechanical hypersensitivityin sham-operated animals did not reveal any influence
of MSC transplantation (Figure 4A-D). MSC injection
did also not affect established PSNL-induced mechanical
hypersensitivity (Figure 4E-H). In accordance with these
data, thermal hypersensitivity was not influenced by
MSC transplantation, neither after PSNL nor after sham
surgery (Figure 5).
Iba1 protein expression is increased after partial sciatic
nerve ligation but not significantly affected by
mesenchymal stem cell injection
Immunohistochemical analysis of Iba1 protein expression
was performed on cryosections of the lumbar spinal cord
(L4-L5) at two different time points: 6 and 21 days after
surgery. For MSC-treated animals, we hypothesised that
microglial activation would trigger the recruitment of the
injected MSCs and/or that MSCs would induce subsequent
mitigation of microglial activation. In sham-operated ani-
mals, microglia were characterised as small and ramified
cells (Figure 6A), while PSNL induced hypertrophied
microglia with less extensive cellular ramification, leading
to a prominent increase in Iba1 immunostaining in the
ipsilateral dorsal horn (Figure 6C). MSC injections did not
change the Iba1 immunostaining in sham-operated ani-
mals (Figure 6B) but they did seem to have an effect in
PSNL animals, as the immunostaining appeared weaker
and less diffuse in the dorsal horn, compared to the tissues
from vehicle-treated PSNL animals (Figure 6C,D). Quanti-
fication of the mean staining intensity confirmed a signifi-
cant increase after PSNL (Figure 6E), which was less
pronounced after MSC injection, even though this differ-
ence failed to be statistically significant. At the end of the
study, sham animals obviously still presented a “non-acti-
vated” morphology of microglia, which was not influenced
by MSC injection (Figure 6A’,B’). PSNL animals still
showed a robust Iba1 immunoreactivity in the dorsal horn
with strongly hypertrophied microglia. These characteris-
tics of microglial activation were not influenced by MSC
injections in the early post-injury period, as indicated in
Figure 6C’,D’. Thus, quantitative analysis of the mean Iba1
staining intensity showed an 94% increase for vehicle-
treated PSNL animals compared to 85% for MSC-treated
PSNL animals (no statistically significant difference)
(Figure 6E’).
Transplanted mesenchymal stem cells do not integrate
into the spinal cord tissue
Prior to injection, MSCs were cultured in the presence of
the thymidine analogue BrdU to facilitate their detection
in the white and grey matter of the spinal cord and to in-
vestigate their differentiation potential after grafting into
the tissue. However, as shown in Figure 7, MSCs did not
integrate into the grey matter. A few BrdU-positive cells
were found in sections from animals sacrificed 6 days after
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Figure 3 Mechanical and thermal hypersensitivity after partial sciatic nerve ligation. Rats were tested for mechanical hypersensitivity (A-C)
by using von Frey filaments, and for thermal hypersensitivity (D-E) with the thermal paw stimulator during 20 days after partial sciatic nerve ligation
(PSNL) surgery. Paw withdrawal threshold (PWT) of the ipsilateral (A) or contralateral (B) hindpaws after mechanical stimulation are expressed as
percentage of the baseline PWT. Paw withdrawal latencies (PWL) of the ipsilateral (D) or contralateral (E) hindpaws after thermal stimulation are
expressed as percentage of the baseline PWL. (C,F) Area under the curve (AUC) analysis of the corresponding graphs. Data shown are mean values
with SEM. For AUC: *P < 0.05, *** P < 0.001, analysed by two-tailed student’s t-test. Day-by-day differences between groups were calculated by whole
sample t-tests with * at least P < 0.05. Each group consisted of 9 to 11 animals.
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mainly around the spinal cord parenchyma in the leftovers
of the pia mater spinalis. In most cases, grafted cells were
found in the area of the anterior spinal artery (Figure 7A,B).
Twenty-one days after surgery (17 days after the last injec-
tion), MSCs could still be detected, but the number of cells
appeared to be lower than after 6 days (Figure 7D,E). The
location appeared to be very similar as compared to the
earlier time point, with the majority of cells being trapped
in the pia mater spinalis. In a few animals, a few isolated
BrdU-positive cells could be detected in the white matter,
but this observation was not representative for all animals.
Mesenchymal stem cells lack a long-term paracrine
influence on cytokine release
The concentration of the cytokines TNFα, IL-1β, IL-6 and
IL-10 in lumbar spinal cord tissue from the ipsilateraldorsal horns (21 days after PSNL) was analysed and quan-
tified by ELISA. The concentration of TNFα was below
the detection level in all samples. Despite the significant
increase in microgliosis 3 weeks after PSNL, we could not
show any influence of the ligation on cytokine concentra-
tions. As indicated in Figure 8, intrathecal injection of
MSCs did not influence the spinal levels of IL-1β, IL-6
and IL-10.
Discussion
We recently reported that a single intrathecal injection
of MSCs in a transgenic animal model of familial ALS
(hSOD1G93A) preserved motor functions, extended sur-
vival and decreased neuroinflammation at the cellular
level [11]. Indeed, the results showed that MSCs inte-
grated into the spinal cord tissue and that microgliosis
could be reduced, whereas astrogliosis was not modified.
Sham - Ipsilateral































































































































































Figure 4 Effect of intrathecally injected mesenchymal stem cells on mechanical hypersensitivity after partial sciatic nerve ligation.
Sham- (A,B) or partial sciatic nerve ligation (PSNL)- (E,F) operated animals either injected with vehicle (“no cells”) or mesenchymal stem cells (MSCs;
“cells”) were tested by using von Frey filaments for 20 days after surgery. Paw withdrawal thresholds (PWT) of the ipsilateral (A or E) or contralateral
(B or F) hindpaws are expressed as percentage of the baseline PWT. (C,D and G,H) Area under the curve (AUC) analysis of the corresponding graphs,
analysed by two-tailed student’s t-test; data shown are mean values with SEM. Day-by-day differences between groups were calculated by whole
sample t-tests with * at least P < 0.05. Each group consisted of 9 to 11 animals.
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factors inhibit the LPS-mediated induction of the inflam-
matory markers IL-1β and TNFα in primary microglial cul-
tures. For the in vivo experiments, we used an animal
model of neuropathic pain caused by PSNL to examine the
therapeutic potential of repeated intrathecally injected
MSCs. Grafted cells were mostly located in the pia mater
spinalis, the meninx surrounding the spinal cord, at day 6
or 21 after injection, while an effect on pain behaviour,
microgliosis or cytokine production could not be observed.
Animals undergoing PSNL developed an extended
microgliosis in the ipsilateral dorsal horn of the spinal
cord and typical behavioural signs of enhanced evokedpain, indicating that the surgery could effectively model
neuropathic pain mechanisms. Stem cell-based therapy
has been shown to ameliorate pain sensations and also
to diminish gliosis in different models of neuropathic
pain, including diabetic neuropathy [30], brain injury
[31], spinal cord injury (SCI) [21] and PNI such as
chronic constriction injury or single ligature nerve con-
striction [22,32,33]. While after SCI, intraspinal applica-
tion of neural stem cells could lead to increased allodynia
due to aberrant axonal sprouting [34,35], for MSCs this
has so far not been reported. Focussing on neuropathic
pain after PNI, publications dealing with MSC treatments





Figure 5 Effect of intrathecally injected mesenchymal stem cells on thermal hypersensitivity after partial sciatic nerve ligation.
Sham- (A,B) or partial sciatic nerve ligation (PSNL)- (E,F) operated animals either injected with vehicle (“no cells”) or mesenchymal stem cells
(MSCs; “cells”) were tested with the thermal paw stimulator for 20 days after surgery. Paw withdrawal latencies (PWL) of the ipsilateral (A or E) or
contralateral (B or F) hindpaws are expressed as percentage of the baseline PWL. (C,D and G,H) Area under the curve (AUC) analysis of the
corresponding graphs, analysed by two-tailed student’s t-test; data shown are mean values with SEM. Each group consisted of 9 to 11 animals.
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Figure 6 Ionized calcium-binding adapter molecule 1 protein expression 6 days and 21 days after partial sciatic nerve ligation.
Immunohistological staining and quantification of the microglial marker ionized calcium-binding adapter molecule 1 (Iba1) at 6 days (A-E) and at
21 days (A’-E’) on the ipsilateral side of the lumbar spinal cord with low and high magnifications. Iba1 staining of sham-operated animals either
vehicle-injected (A,A’) or MSC-injected (B,B’) and PSNL animals with vehicle (C,C’) or MSCs (D,D’). Scale bar represents 500 μm. (E,E’) Quantification of
the mean grey intensity within the total dorsal horn with SEM, two-way analysis of variance and Tukey post-hoc test for statistical analysis, *P < 0.05
and **P < 0.01. Groups at 6 days after PSNL consisted of 3 to 4 animals and groups at 21 days after PSNL consisted of 5 to 7 animals.
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with the present work or with each other as they differ in
several aspects of the experimental set-up, such as the
number of cells injected, the site and method of injection,
the time point of administration (before or after the injury)
and the type of injury. Besides diminishing pain behaviour,MSC treatments in PNI also decreased astro- and microglial
cell activation as well as reduced levels of pro-inflammatory
cytokines, such as IL-1β and IL-17. Furthermore, increased
levels of anti-inflammatory cytokines and markers, such
as IL-10 and CD206, could be detected [23,36]. The up-
regulation of CD206 is particularly interesting, as it
AB C
D E
Figure 7 Fate of mesenchymal stem cells after intrathecal
injection 6 days and 21 days post-partial sciatic nerve ligation.
Immunohistological staining of the lumbar spinal cord (L4/L5) of partial
sciatic nerve ligation (PSNL) animals injected with mesenchymal stem
cells (MSCs). Bromodeoxyuridine (BrdU)-labelled MSCs appear red and
cell nuclei blue. Cells were only validated as BrdU-positive when also
showing a blue labelling. (A) Full spinal cord section 6 days after PSNL.
Scale bar represents 1000 μm. (B,C) Representative photographs 6 days
after PSNL. Scale bar represents 400 μm. (D,E) Representative
photographs 21 days after PSNL. Arrows indicate BrdU-positive cells.
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the pro-inflammatory type M1 to the anti-inflammatory
type M2 [37], even though a single marker cannot
unequivocally identify the functional orientation of a
macrophage or microglial cell [38]. MSCs have already
been shown to support this phenotypic switch [39],revealing one of the putative mechanisms of how MSCs
exert their anti-inflammatory action. On the basis of these
data, it was rather surprising not to detect any significant
impact of MSCs on pain behaviour or the associated neu-
roinflammatory processes in the present study. The lack of
effect of MSC treatment in our hands raises questions in
regard to the methodical design, where different issues
should be reconsidered and discussed, namely: (1) the
amount of grafted cells, (2) the timing (time point of treat-
ment/duration of treatment/observation time), (3) the
route of administration and (4) the model of inflammation.
While the amount of stem cells used in neuropathic
pain studies varies strongly and ranges from 5 × 104 to
107 MSCs [33], we grafted, consistent with our experi-
ence in intrathecal injections of cells [11], 106 cells each
day but on 3 consecutive days to ensure a constant de-
livery at a stage where maximal inflammation was ex-
pected [29]. It was previously shown that single
intraventricular injections of 5 × 104 MSCs resulted in
diminished pain-like behaviour and decreased densities
of activated astro- and microglial cells [23]. A study test-
ing different cell quantities ranging from 104 to 106 in
an ALS mouse model showed that, in general, higher cell
numbers are associated with a greater benefit [40]. A
similar finding was recently published in a model of ex-
perimental neuropathy, but with stem cells from neural
origin [32]. Nevertheless, this concept shows limitations
as, beyond a certain number of grafted cells, the ob-
tained benefit cannot be augmented by additional injec-
tions [41]. Furthermore, as we observed in preliminary
experiments, it has been described that high amounts of
cells cause clustering in the microinjection cannula,
which in turn may cause cell damage and decreased via-
bility [23]. As clustering can be avoided, delivery via
catheter injection does not affect the viability or cell
function of MSCs [42]. Also, since we decided to deliver
the cells locally and not systemically, we are confident
that the amount of 106 cells per injection was an appro-
priate option.
The choice of an adequate time point for cell injection
likely constitutes one of the most important issues in the
experimental design of stem cell grafting. In the present
study we employed repetitive injection of MSCs on days
2, 3 and 4 following PSNL surgery, when a maximal in-
flammatory response is expected, while other investiga-
tors chose single injections on day 4 or 7 after injury
[21,23,36]. In the publications of Musolino and col-
leagues [22] and Klass and colleagues [33], the adminis-
tration of MSCs coincided with the injury, even though
one could argue that this paradigm is hardly transferable
to clinical settings. In the latter study, MSCs did not pre-
vent pain, but promoted recovery from pain starting
10 days after injury, leading to a complete reversal,
which is contrary to our observations. In this regard, a
AB
C
Figure 8 Cytokine production in the ipsilateral dorsal horns
21 days post-partial sciatic nerve ligation. Concentrations of (A)
IL-1β, (B) IL-6 and (C) IL-10 were measured in supernatants of lysed
tissues as derived from the ipsilateral dorsal horns of the L3-L6 spinal
cord region. Concentrations of TNFα were below the detection level.
Data represent mean with SEM, analysed by two-way analysis of
variance followed by Tukey post-hoc test. Each group consisted of 4
to 6 animals. MSC, mesenchymal stem cells; PSNL, partial sciatic
nerve ligation.
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general be worth considering. However, as the severity
of pain is associated with the degree of microglial activa-
tion [2], and since we observed a trend for microgliosis
attenuation by MSC-treatment 6 days post-PSNL, which
was absent again 21 days post-PSNL, a delayed improve-
ment was hardly expected in the present study. Further-
more, we were not able to detect changes in cytokine
release caused by PSNL on postoperative day 21, after
completion of the behavioural testing of the same animal
cohort. This period was presumably too long to detect
changes, as we also failed in an earlier study to identify
differences in the gene expression of pro-inflammatory
genes such as IL-1β, TLR4 and Nox2, 21 days after
PSNL [2]. Previous studies describing successful detec-
tion of changes in cytokine concentrations using ELISA
indeed focussed on earlier time points after nerve
ligation or transection, such as 3, 7 or maximally 11 days
post-surgery [9,43-45].
Besides the amount of grafted cells, the route of cell ad-
ministration also prevalently differs in the literature and
should be a main topic while discussing the study design.
Frequently, cell delivery in rats is carried out by systemic
injection via the tail vein, which represents a less invasive
administration route. When choosing this approach, the
amount of grafted cells usually should be rather high as
the majority will be trapped in the lungs or be cleared by
peripheral macrophages before reaching their destination
[46]. Surprisingly, studies using intravenous injection of
MSCs in neuropathic pain reported striking results, such
as complete reversal of hyperalgesia [33]. Furthermore,
MSCs were found to accumulate in the L4-L5 spinal cord
and pre-frontal cortex, revealing their specificity for en-
graftment in neuropathic pain controlling and processing
areas [36]. In regard to the use in neuropathic pain
models, local administration of MSCs by intraganglionic
[22], intraparenchymal [21] or intraventricular [23] injec-
tions have been reported, whereas intrathecal approaches
have not been tested so far. While one could speculate
that direct delivery of cells into the cerebrospinal fluid at
the L4-L5 level of the spinal cord would improve the mi-
gration to the site of inflammation as well as the integra-
tion into the tissue, we had to realise that tissue
infiltration was here far less efficient compared to other
ways of administration. Interestingly, the same observa-
tion has been made for the intrathecal delivery of MSCs
after SCI, when cells were injected within the acute in-
flammatory phase (days 1 to 7) [47]. Here, grafted cells
were also found attached to the pia mater or accumulated
around the anterior spinal artery. In contrast, rats injected
repeatedly within the subacute phase (days 7 to 14) on
days 7, 8 and 9 after SCI showed functional recovery,
while MSCs incorporated into the central lesion. One of
our initial hypotheses proposed that MSCs would be
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moting their migration to the site of inflammation, in our
case to the ipsilateral dorsal horn. While MSCs were
detected at the lumbar level (L4-L5) of the spinal cord,
these rarely entered the tissue, but were “trapped” in the
pia mater spinalis, suggesting that the inflammation
caused by PSNL might not have been strong or long
enough to attract the cells. Indeed, it has been demon-
strated that the degree of injury is important for the
survival and tissue integration of MSCs [21,48]. This
might also explain why our results differ from our former
study in ALS. While PSNL causes a rather acute inflam-
mation, ALS-associated neuroinflammation is a chronic
process, which accompanies the disease onset and in-
creases continuously until end-stage. Thus, we can only
hypothesise that important features of chronic inflamma-
tion, which might be essential for the proper attraction of
MSCs from the cerebrospinal fluid and their migration
into the nervous parenchyma were still absent in the
model of peripheral nerve ligature.
Taken together, we may only suggest that MSC pene-
tration through the pia mater spinalis and infiltration
into the inflamed spinal cord parenchyma might be
more challenging than expected. Cizkova and colleagues
[47] speculated that early injected MSCs cannot inte-
grate into the spinal cord parenchyma as they are
repelled by a too strong inflammatory response after
injury. Nevertheless, we rather hypothesise that the
mechanical border surrounding the spinal cord surface,
comprising the pia mater spinalis, its basal membrane
and the subjacent glia limitans superficialis, is preserved
intact during the first days of inflammation. This idea is
supported by the fact that within the first 7 days after
SCI, due to inflammatory processes, the basement mem-
brane is drastically altered and astrocytic foot processes,
which compose the glia limitans, retract from the base-
ment membrane. The progression of these events even
coincides with a pronounced infiltration of inflammatory
cells into the spinal cord parenchyma [49,50].
Conclusion
Repetitive intrathecal delivery of MSCs on day 2, 3 and
4 after PSNL neither affected pain sensations such as
allodynia and hyperalgesia, nor decreased microglial ac-
tivation that developed in the ipsilateral spinal cord.
Twenty-one days after grafting, labelled MSCs could be
relocated in the pia mater spinalis, but did not integrate
into the spinal cord parenchyma. Thus, early intrathecal
delivery of MSCs in the specific model of PSNL has no
beneficial effects on neuropathic pain or the underlying
neuroinflammatory processes. After critical analysis of
our data and confrontation with the literature, we are
convinced that the amount of cells and the time points
of administration were chosen correctly in the presentstudy. Nevertheless, the selected application route of
intrathecal injection seems inefficient in regard to the in-
tensity level of neuroinflammation in the spinal cord after
PSNL. To accurately evaluate the therapeutic potential of
MSCs in this specific model, further studies should focus
on the reassessment of alternative administration routes.
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